SC 717
Alternative Names: SC-717Latest Information Update: 28 Sep 2024
At a glance
- Originator ViroCure
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Solid-tumours in South Korea
- 19 Aug 2020 SC 717 is available for licensing as of 19 Aug 2020. https://www.virocure.net/technology (Virocure pipeline, September 2020)
- 19 Aug 2020 ViroCure has patent protection for SC 717 in South Korea (ViroCure pipeline, September 2020)